Immunovant (IMVT)
(Delayed Data from NSDQ)
$27.17 USD
-0.58 (-2.09%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $27.13 -0.04 (-0.15%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Immunovant, Inc. [IMVT]
Reports for Purchase
Showing records 1 - 20 ( 99 total )
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Pedal to the Metal for Immunovant as It Looks to Keep Pace with Competitors in FcRn Space; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Initial Data in Grave''s Disease Gives Immunovant an Indication to Itself; Target to $51
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
''1402 Confirms Profile and Ready to Move into the Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for IMVT 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
With SAD and Early MAD Data in the Bank, Eyes Turn to Final Phase 1 MAD Readout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D